These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 23598819

  • 1. Emerging treatments in chemotherapy-induced nausea and vomiting.
    Grunberg SM, Slusher B, Rugo HS.
    Clin Adv Hematol Oncol; 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y, Sun W, Gu D, Yang J, Xu Z, Chen J.
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S, Buchner D, Craver C, Gayle J.
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [Abstract] [Full Text] [Related]

  • 7. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB.
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C, Slusher BS.
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM.
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Emerging drugs for chemotherapy-induced emesis.
    Navari RM, Province PS.
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M, Tsukuda M.
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
    Schwartzberg LS, Rugo HS, Aapro MS.
    Clin Adv Hematol Oncol; 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14. PubMed ID: 25856052
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.